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Abstract
Background: Randomized evidence for vaccine immunogenicity and safety is urgently needed in the setting of pandemics
with new emerging infectious agents. We carried out an observational survey to evaluate how many randomized controlled
trials testing 2009 H1N1 vaccines were published among those registered, and what was the time lag from their start to
publication and from their completion to publication.
Methods: PubMed, EMBASE and 9 clinical trial registries were searched for eligible randomized controlled trials. The units of
the analysis were single randomized trials on any individual receiving influenza vaccines in any setting.
Results: 73 eligible trials were identified that had been registered in 2009–2010. By June 30, 2011 only 21 (29%) of these
trials had been published, representing 38% of the randomized sample size (19905 of 52765). Trials starting later were
published less rapidly (hazard ratio 0.42 per month; 95% Confidence Interval: 0.27 to 0.64; p,0.001). Similarly, trials
completed later were published less rapidly (hazard ratio 0.43 per month; 95% CI: 0.27 to 0.67; p,0.001). Randomized
controlled trials were completed promptly (median, 5 months from start to completion), but only a minority were
subsequently published.
Conclusions: Most registered randomized trials on vaccines for the H1N1 pandemic are not published in the peer-reviewed
literature.
Citation: Ioannidis JPA, Manzoli L, De Vito C, D’Addario M, Villari P (2011) Publication Delay of Randomized Trials on 2009 Influenza A (H1N1) Vaccination. PLoS
ONE 6(12): e28346. doi:10.1371/journal.pone.0028346
Editor: Neil R. Smalheiser, University of Illinois-Chicago, United States of America
Received October 10, 2011; Accepted November 7, 2011; Published December 2, 2011
Copyright:  2011 Ioannidis et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors have no support or funding to report.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: lmanzoli@post.harvard.edu
Introduction
Randomized controlled trials are pivotal in providing reliable
information about the effectiveness and safety of vaccines. In the
case of rapidly emerging pandemics with newly discovered
infectious agents, such as the 2009 influenza A(H1N1) virus, the
availability of such information becomes even more time-sensitive
[1]. While some preliminary information from such trials can be
provided in confidential communications to regulatory and public
policy authorities for immediate decisions, the scientific peer-
review process offered by journals provides the ultimate possible
guarantee about the quality of these data and the balanced
presentation of the results. In an evolving, emerging pandemic for
which a new vaccine is needed, it is usually possible to recruit a
sufficient number of interested participants in limited time.
Moreover, outcomes can be assessed quickly in vaccine trials
when the primary emphasis is on immunological response
(assessed in a few weeks) and short-term adverse events. However,
are such trials published also quickly in the peer-reviewed
literature?
To address this question, we evaluated empirically the
publication delay of randomized trials of 2009 H1N1 vaccines
[2]. We considered all trials of these vaccines registered in main
trial registries in 2009 and 2010 and evaluated whether these trials
have published any data in the peer-reviewed literature by the end
of June 2011 and also how long it took from the time they started
until they published their results.
Methods
Randomized controlled trials evaluating 2009 influenza
A(H1N1) vaccine immunogenicity and safety in healthy humans
who had not previously received 2009 H1N1 vaccines were
retrieved through searches in MEDLINE and EMBASE. We
focused on trials that had been registered in at least one of several
clinical trial registries (Cochrane Controlled Clinical Trial
Register, ISRCTN, US ClinicalTrials.gov, WHO ICTRP, GSK
Clinical Study Register, and Indian, Australian New Zealand and
Chinese Clinical Trial Registries) in 2009 or 2010. We had no
language restriction and the last update of searches for identifying
published trials was performed on June 30, 2011. Search terms
were ‘‘vaccine OR vaccines OR vaccination’’, and ‘‘H1N1 OR
pandemic’’ in all fields. The bibliographies of all relevant articles
including reviews were reviewed for further references [2].
Randomized controlled trials were eligible for consideration
regardless of the doses and formulations of the vaccine that they
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had been published or not. We screened potentially eligible
registered trials to avoid double-entry of the same trial that may
have been identified from two different sources. Moreover,
whenever a trial had two or more publications of its results on
the same sample size, we focused on the earliest published report
in a peer-reviewed journal that provided any evidence on
immunogenicity and/or safety in the study population. Whenever
the same study published two or more reports with increasing/
expanding sample sizes over time, we considered the incremental
amount of evidence that became available at each publication, e.g.
if a trial reported on 2000 patients in October 2009 and on 12000
patients in December 2009, we considered that randomized
evidence on 2000 patients became available in the published
literature in October 2009 and then evidence on another 10000
patients became available in December 2009.
For each eligible trial that had started and had been registered
as starting before the end of 2010, we recorded the registry
number; the sample size (actual, if completed; and anticipated, if
not fully recruited yet); the sponsor(s); the date of starting; whether
it was published or not; and the date of publication in the peer-
reviewed literature for those trials that were published. For trials
published online ahead of print, we used the time of electronic
publication. We also collected information on the reported date of
primary completion for trials that had been completed. Informa-
tion on the date of completion may be less standardized across
trials and thus less reliable, because occasionally some trialists and
sponsors continue to report a trial as not yet completed even after
it has published its main results, if there are plans for additional
analyses or longer follow-up. Therefore, whenever the reported
date of completion of a trial was within less than 3 months of its
publication date (7 trials), we imputed the date of completion to be
3 months before the publication date. Unpublished trials with
anticipated completion dates after June 30, 2011, are considered
non-completed and time is censored on June 30, 2011 for all
analyses.
We evaluated the time from starting a trial to its publication using
Kaplan-Meier analysis considering all registered trials. We also
evaluated withthelog-ranktest whether the time-to-publication was
different for different sponsors, and then tested with Cox
proportional hazards analysis whether there was any evidence that
the risk of publication was dependent on the sponsor, sample size
(log-transformed) and date of starting. We performed both
univariate and multivariate analyses, in which we included a priori
the three covariates above. Secondary analyses evaluated the time
from starting a trial until its completion and the time from
completion of a trial to its publication. The proportional hazards
assumptionwaschecked forall modelsusing theSchoenfeld test and
plotting Nelson-Aalen cumulative hazards estimates.
Finally, we evaluated using Spearman’s rank correlation
coefficient whether trials published early were selected for
publication by journals with higher impact factor (according to
Thomson ISI Journal Citation Reports, Edition 2009) than trials
published later. Analyses were conducted in Stata 10.1 (Stata
Corp., College Station, TX, USA, 2007). P-values are two-tailed.
Results
We identified 73 randomized controlled trials of 2009 H1N1
vaccines that had been registered in 2009–2010. Of those, only 21
(29%) had been published by June 30, 2011. Figure 1A shows the
Kaplan-Meier plot for the time-to-publication. The risk for a trial
remaining unpublished was 69% at a year and a half after starting.
The majority of the trials (57/73) had been sponsored by the
industry testing vaccines manufactured by a total of 14 different
companies (GSK n=16, Novartis n=12, Sanofi-Aventis n=7,
CSL n=4, Panacea Biotec n=4, Sinovac n=2, Bharat Biotech
n=2, MedImmune n=2, Baxter n=2, Adimmune n=2, Hualan
Biological Bacterin n=1, Novavax n=1, VaxInnate Corporation
n=1, Vaxine Pty n=1). Another 16 trials were sponsored by not-
for-profit organizations, but each of these trials also tested vaccines
from a single company with only three exceptions (NCT01000584,
ISRCTN92328241, NCT00980850) that tested vaccines by two
different companies. Our analysis showed no significant difference
in the time-to-publication across the major sponsors (log-rank p-
value=0.39, figure 1B).
Overall, the total sample size of the 73 trials amounts to 52765
participants. Of those, the 21 published trials include data on 19905
participants (38%). Figure 2 shows the total cumulative sample size
over time of trials that were launched and of those that had been
published over time. As shown, by November 2009, trials had been
launched that cumulatively cover about 78% of the total randomized
trial effort. Mostof the remaining randomized evidence (total of 94%)
had been launched by February 2010, and very little additional
randomized evidence was collected in trials launched later in 2010.
The published randomized data first appeared on September 10,
2009 with two small randomized trials published online in the New
England Journal of Medicine (total n=416), and the published
evidenceincreased ton=15319 bytheendofthecalendaryear2009,
with a total of 9 trials published on 5 different vaccines. No other trials
were published until March 2010, when the 2009–2010 pandemic
season was ending in the Northern hemisphere. During the following
15 months, another 12 trials were published, all of them with modest
sample sizes (107–1313 participants each).
In univariate analyses (Table 1), trials starting later were
published far less rapidly (hazard ratio 0.42, 95% confidence
interval (CI), 0.27 to 0.64 per month, p,0.001). In fact, none of
the trials that started after October 2009 have been published as of
June 30, 2011. The analysis found no trend for faster publication
of larger trials (hazard ratio 0.93, 95% CI, 0.58 to 1.48, per 10-fold
increase in sample size, p=0.8). We also found no difference in the
time-to-publication for trials sponsored by not-for-profit structures
vs companies (hazard ratio 0.52, 95% CI, 0.15 to 1.78 per month,
p=0.3). Multivariate analyses confirmed univariate results:
adjusting for sample size and sponsor (not-for profit vs companies),
the hazard ratio of publication was 0.36 (95% CI, 0.23 to 0.58,
p,0.001) for each month of later start.
Figure 3 shows the Kaplan-Meier plot for the time from starting
to completion (Figure 3A) and for the time from completion to
publication of a trial (Figure 3B). The median time from starting to
completion based on the Kaplan-Meier analysis was 5 months. We
found that the time to completion did not differ for trials starting
later, for those with company sponsors, or for those that were
larger compared with earlier, not-for-profit, and smaller trials,
respectively (Table 1).
In addition to the 21 published trials, 47 of the 52 unpublished
RCTs were reported as completed (90.4%). After completion,
some trials were published very fast (within 5 or less months), but
then the publication rate declined; at 18 months after completion
the estimated risk of remaining unpublished was 64%. Again, trials
completed later were published less rapidly (hazard ratio 0.43,
95% CI, 0.27 to 0.67 per month p,0.001). Only one of the trials
that were completed after April 2010 has been published as of
June 30, 2011. The analysis showed no difference in the time-to-
publication after completion in trials with different sponsors and
sample sizes (both p.0.05) (Table 1).
As shown in Figure 4, the trials published later appeared in
journals with lower impact factor (rank correlation coefficient
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in New England Journal of Medicine, Lancet, or JAMA. Only 2 of
the 10 trials published in 2010 appeared in journals with impact
factor above 6 and even these did not appear in any of the
aforementioned 3 top-impact journals. The only two trials
published to-date during 2011 were published together as a single
paper (2 in 1) in a journal with impact factor less than 2.5.
Discussion
Two years after the emergence of the influenza 2009 H1N1
pandemic and well after the end of both the 2009–2010 and 2010–
2011 seasons only a minority of the registered randomized
evidence on the potential vaccines has been published. The global
response to the pandemic was ultrafast
1 and this included the
early launch of numerous randomized trials for testing many
different vaccine formulations. However, very limited randomized
evidence was published in the peer-reviewed literature by the time
major decisions were made in the fall of 2009 about the use of
these vaccines [3]. Peer-reviewed data appeared in the highest-
impact journals on over 15,000 participants by the end of 2009,
but relatively limited evidence was published in 2010 or 2011 and
none of the trials launched after October 2009 have been
published as of June 2011, well after the 2010–2011 influenza
season has finished. Trials were generally completed promptly,
with a median time of 5 months from starting until completion.
Figure 1. Time from start to publication for 2009 H1N1 vaccine trials overall (A) and according to sponsor (B).
doi:10.1371/journal.pone.0028346.g001
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trials with short-term follow-up. The major problem was the delay
after completion of the trials. Trials that started late and similarly
trials completed late had limited chances of getting published.
Other investigators have described that for yet another major
epidemic, SARS, the proportion of relevant research published
during the epidemic was limited [4,5]. Most literature on SARS
was published after the epidemic had ceased to be a problem. It is
unknown what portion of the conducted research was actually
never published at all, as interest in SARS declined sharply in later
years in most circles. However, the core literature of SARS did not
involve randomized trials, while vaccine trials were of pivotal
interest for the 2009 H1N1 pandemic.
The publication of clinical trial results is generally considered an
ethical imperative. Much as a survey with 30–40% response rate is
considered of questionable validity, a randomized trials agenda
where only 38% of the data have been published poses concerns.
Lack of publication of randomized trials, often coupled with a
biased selection against trials with specific results, is well
documented across very diverse fields [5–13]. Only 42% of an
unselected sample of trials completed in 2005 had been published
by the end of 2007 [14]. Randomized controlled trials, in
particular phase III trials, can vary substantially on the time they
take to conduct, analyze and publish. This time includes
enrolment, patient follow-up, data analysis, manuscript prepara-
tion, peer-review, possible rejections, and publication phases [10].
For trials that require substantial follow-up, results may be
published many years after the trial starts [10].
For vaccine trials where timely evidence is needed, the
evaluation of the primary immunogenicity and short-term safety
outcomes can be performed quickly and trials are completed in
minimal time. Therefore the rate-limiting steps are manuscript
preparation, review and publication of the results. Our data do not
allow us to know with certainty which of these steps in the
publication process may have been most retarding for influenza
H1N1 vaccine trials. However, it is reasonable to suspect that
authors, reviewers and journals may all show urgency in writing,
reviewing and publishing results, if these become available early
on. This is proven by the very rapid publication of the very first
few trials, all of which were published in record time in the most
prestigious medical journals and attracted enormous attention in
2009 [15]. The three trials published in New England Journal of
Medicine in 2009 [16–18] received according to the Thompson
Reuters Web of Knowledge 80, 58, and 58 citations, respectively,
Figure 2. Cumulative sample size in launched and published trials of 2009 H1N1 vaccines over time.
doi:10.1371/journal.pone.0028346.g002
Table 1. Predictors of time to completion and time to publication: hazard ratio (HR) and 95% confidence interval (CI) in univariate
Cox models.
Start to publication Start to completion Completion to publication
HR (95% CI) HR (95% CI) HR (95% CI)
Calendar time (per 1 month later) 0.42 (0.27–0.64) 0.92 (0.85–1.02) 0.43 (0.27–0.67)
Sample size (per 10-fold increase) 0.93 (0.58–1.48) 0.98 (0.76–1.26) 0.88 (0.52–1.47)
Not-for-profit vs companies 0.52 (0.15–1.78) 0.99 (0.54–1.79) 0.48 (0.14–1.73)
doi:10.1371/journal.pone.0028346.t001
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the tip of the iceberg of the randomized evidence on this topic.
Interest in the other trials diminished and faded over time, in
particular after the fall of 2009. Later published trials appeared in
journals of far lesser citation impact. By 2011 two trials were
published as a single paper in a low impact-factor journal, while
trials of similar magnitude could have been published in a major
journal in 2009.
Eventually, less than 30% of the trials registered in 2009–2010
were published by mid-2011. This lack of published data for the
majority of the evidence creates difficulties in systematically
appraising the overall randomized agenda of influenza H1N1
vaccines [19]. Moreover, numerous formulations have been
developed from at least 14 different companies and it is not easy
to extrapolate inferences from one formulation to another.
Fragmentation and lack of publication shrink the evidence-base
on a topic of major public health importance.
Some limitations should be acknowledged. First, we do not
know the results of the unpublished trials and few of them (n=5)
seem not even completed yet. There is a substantial literature in
Figure 3. Time from start to completion (A) and from completion to publication (B) for 2009 H1N1 vaccine trials.
doi:10.1371/journal.pone.0028346.g003
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favourable or even ‘‘negative’’ results as compared with more
rapidly published trials [10,12]. However, we have no evidence for
such a bias in 2009 H1N1 vaccine trials. Most of these trials do not
have results that can be categorized as ‘‘positive’’ and ‘‘negative’’
anyhow, since they compare different doses and formulations and,
with the exception of very low doses, they are likely to generate
substantial immunogenicity. Moreover, safety seems to have been
very well established currently, at least in the short-term, based on
observational studies of thousands of people who received 2009
H1N1 vaccines [20]. However, the lack of published information
on the majority of the randomized data on immunogenicity does
not allow estimating with high reliability the relative merits of
different formulations.
Second, it is possible that some additional trials exist that are not
registered. Then our reported non-publication rates may even
underestimate the magnitude of this problem. For example, an
updated search at the time of the revision of this manuscript
(October 25, 2011) identified two otherwise eligible trials [21,22]
that were recently published (in August and September 2011,
respectively) and that made no mention to registration. This is
despite the fact that the publishing journals for these trials have
instructions to the authors asking for registration of randomized
trials and documentation of the registration number. The
denominator of the total number of launched unregistered trials
is by default unknown. Otherwise, the quality of the registry-
recorded information is probably adequate. One potential
exception is that, as we acknowledge in the Methods, information
on the time of completion of a trial based on registry information
can be sometimes tenuous, thus analyses using the date of
completion require extra caution.
Finally, some additional trial results may have been made
available by companies to select committees of key organizations
and experts/insiders in the H1N1 field. Such insider-views and
privileged communications are typical in almost any medical field.
However, this does not negate the importance of publishing the
results in the wider peer-reviewed literature. When we checked for
such publicly available information, we found only scarce and
fragmented data on H1N1 trial results at the FDA website, and
only a minority of the trial reports posted on the EMA website
reported vaccine compositions (covered under manufacturer’s
codes), thus it was impossible to ascertain which formulations are
most immunogenic or safe [23–25]. Having widely accessible data
in regulatory agencies and also in the peer-reviewed literature may
diminish the publication delay issue. Such public data transpar-
ency will also help address concerns about the differences observed
between regulatory-submitted and literature-published results that
have been documented for medication trials [26–27].
Expedited posting, review and timely online publication of
randomized results may also be feasible, employing evolving
structures such as PLoS Currents: Influenza [28]. However, one
has to ensure that such online options employ also rigorous and
transparent peer-review and also are utilized for this purpose. To
our knowledge, none of these trials were posted in PLoS Currents:
Influenza. A perusal of the 75 articles in PLoS Currents: Influenza
as of October 24, 2011 shows that none of them are randomized
Figure 4. Scatter plot showing the impact factor of published randomized trials by time of publication.
doi:10.1371/journal.pone.0028346.g004
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Investigators may feel that there is an opportunity cost in writing
up manuscripts for publication if they feel that they would no
longer be attractive and cited and would most likely be published
only in low impact journals. However, one has to find incentives
for the majority of trials to become published after peer-review,
including the majority of trials that did not make it into publication
during the early phase of golden opportunity for publication in
major journals. This information may be of critical importance in
giving a more comprehensive picture of the available evidence for
the future, for any subsequent pandemics by the same virus.
Remedying the publication system for such trials would also be
critical for improving the completeness of the randomized
evidence for future pandemics by other infectious agents.
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